Effectiveness of etrasimod in patients with Ulcerative Colitis
Research type
Research Study
Full title
Effectiveness of Etrasimod on disease activity and patient-reported outcomes in Ulcerative Colitis - EFFECT-UC
IRAS ID
333370
Contact name
Peter Irving
Contact email
Sponsor organisation
Pfizer Ltd
Duration of Study in the UK
3 years, 10 months, 1 days
Research summary
Ulcerative colitis is an inflammatory bowel disease of the digestive tract. Those with moderate to severe disease activity may have up to 10 bowel movements per day, rectal bleeding, and abdominal pain which can have a substantial impact on their daily activities and quality of life. The purpose of this study is to understand how effective etrasimod, a newly available treatment, is at improving the measurable symptoms of Ulcerative Colitis in patients receiving the treatment through routine standard of care. The study will be conducted in approximately 15 sites in the UK along with other countries in Europe. Patients will be followed for 1 year after starting treatment. Etrasimod effectiveness will be measured by patient reported symptomatic remission and measures assessed through routine standard of care.
REC name
London - London Bridge Research Ethics Committee
REC reference
24/PR/0103
Date of REC Opinion
8 Feb 2024
REC opinion
Favourable Opinion